Expert Interviews

Alex Tessnow, MD, concludes this series with key final takeaways.

Alex Tessnow, MD, reviews treatment approaches for elderly patients with hypothyroidism.

Alex Tessnow, MD, discusses the common symptoms and red flags associated with hypothyroidism in elderly patients.

Alex Tessnow, MD, highlights the variability of hypothyroidism among elderly patients.

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

Professor MeiLan Han, MD, MS, details inclusion of the 2 new medications and how the additions reflect a focus on disease heterogeneity and precision medicine in in COPD.

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.

When a patient with Alzheimer dementia becomes agitated, check the physical environment for a trigger before pulling the trigger on a medication, dementia expert George Grossberg, MD, recommends.

The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.